Gerstein Fisher’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Gerstein Fisher’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-21,332	Closed	-$864K	–	439
2016 Q1	$864K	Hold	21,332	–	–	0.12%	149
2015 Q4	$1.89M	Buy	+21,332	New	+$1.68M	0.26%	80

Other funds holding EGRX

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Gerstein Fisher's EGRX Position: Q2 2016 in Review

Gerstein Fisher sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2016, closing a stake of 21,332 shares — an estimated $864K sold.

Gerstein Fisher first reported a position in EGRX in Q4 2015 and held it in 2 quarters. The position peaked at $1.89M in Q4 2015. 116 funds tracked by Wall St. Rank hold EGRX as of Q2 2016.

Gerstein Fisher reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Gerstein Fisher sold 21,332 Eagle Pharmaceuticals, Inc. shares in Q2 2016, an estimated $864K.
Gerstein Fisher first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
Gerstein Fisher's Eagle Pharmaceuticals, Inc. position peaked at $1.89M in Q4 2015.
116 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2016.

Based on Gerstein Fisher's 13F filing for Q2 2016, filed 8 Aug 2016.